Verapamil Targets Membrane Energetics in Mycobacterium tuberculosis

Amphiphilic Indole Derivatives as Antimycobacterial Agents: Structure–Activity Relationships and Membrane Targeting Properties

(2017) Tianming Yang et al.   JOURNAL OF MEDICINAL CHEMISTRY

Immune activation of the host cell induces drug tolerance inMycobacterium tuberculosisboth in vitro and in vivo

(2016) Yancheng Liu et al.   JOURNAL OF EXPERIMENTAL MEDICINE

Morphological changes and differentially expressed efflux pump genes in Mycobacterium tuberculosis exposed to a rifampicin and verapamil combination

(2016) Katiany R. Caleffi-Ferracioli et al.   TUBERCULOSIS

Boromycin Kills Mycobacterial Persisters without Detectable Resistance

(2016) Wilfried Moreira et al.   Frontiers in Microbiology

Design, Synthesis, and Evaluation of Novel Hybrid Efflux Pump Inhibitors for Use against Mycobacterium tuberculosis

(2016) Malkeet Kumar et al.   ACS Infectious Diseases

Can the addition of verapamil to bedaquiline-containing regimens improve tuberculosis treatment outcomes? A novel approach to optimizing TB treatment

(2015) Geetha Srikrishna et al.   Future Microbiology

Study of efflux pump gene expression in rifampicin-monoresistant Mycobacterium tuberculosis clinical isolates

(2015) Guilian Li et al.   JOURNAL OF ANTIBIOTICS

The Psp system ofMycobacterium tuberculosisintegrates envelope stress-sensing and envelope-preserving functions

(2015) Pratik Datta et al.   MOLECULAR MICROBIOLOGY

The association between sterilizing activity and drug distribution into tuberculosis lesions

(2015) Brendan Prideaux et al.   NATURE MEDICINE

Antiinfectives targeting enzymes and the proton motive force

(2015) Xinxin Feng et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Enhancement of antibiotic activity by efflux inhibitors against multidrug resistant Mycobacterium tuberculosis clinical isolates from Brazil

(2015) Tatiane Coelho et al.   Frontiers in Microbiology

Energy Metabolism and Drug Efflux in Mycobacterium tuberculosis

(2014) P. A. Black et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Comprehensive physicochemical, pharmacokinetic and activity profiling of anti-TB agents

(2014) Suresh B. Lakshminarayana et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Verapamil, and Its Metabolite Norverapamil, Inhibit Macrophage-induced, Bacterial Efflux Pump-mediated Tolerance to Multiple Anti-tubercular Drugs

(2014) Kristin N. Adams et al.   JOURNAL OF INFECTIOUS DISEASES

Ofloxacin Resistance in Mycobacterium tuberculosis Is Associated with Efflux Pump Activity Independent of Resistance Pattern and Genotype

(2014) Zhaogang Sun et al.   Microbial Drug Resistance

Isocitrate lyase mediates broad antibiotic tolerance in Mycobacterium tuberculosis

(2014) Madhumitha Nandakumar et al.   Nature Communications

Acceleration of Tuberculosis Treatment by Adjunctive Therapy with Verapamil as an Efflux Inhibitor

(2013) Shashank Gupta et al.   AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE

Two Human Host Defense Ribonucleases against Mycobacteria, the Eosinophil Cationic Protein (RNase 3) and RNase 7

(2013) David Pulido et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Reduced Drug Uptake in Phenotypically Resistant Nutrient-Starved Nonreplicating Mycobacterium tuberculosis

(2013) Jansy Sarathy et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Efflux Inhibition with Verapamil Potentiates Bedaquiline in Mycobacterium tuberculosis

(2013) Shashank Gupta et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Collapsing the Proton Motive Force to Identify Synergistic Combinations against Staphylococcus aureus

(2013) Maya A. Farha et al.   CHEMISTRY & BIOLOGY

Effect of repeated dosing on rifampin exposure in BALB/c mice

(2013) Vinayak Hosagrahara et al.   EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES

Role of the Mmr Efflux Pump in Drug Resistance in Mycobacterium tuberculosis

(2012) L. Rodrigues et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Contribution of Efflux to the Emergence of Isoniazid and Multidrug Resistance in Mycobacterium tuberculosis

(2012) Diana Machado et al.   PLoS One

Rifampicin Reduces Susceptibility to Ofloxacin in Rifampicin-resistantMycobacterium tuberculosisthrough Efflux

(2011) Gail E. Louw et al.   AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE

Drug Tolerance in Replicating Mycobacteria Mediated by a Macrophage-Induced Efflux Mechanism

(2011) Kristin N. Adams et al.   CELL

Activity-Based Metabolomic Profiling of Enzymatic Function: Identification of Rv1248c as a Mycobacterial 2-Hydroxy-3-oxoadipate Synthase

(2010) Luiz Pedro S. de Carvalho et al.   CHEMISTRY & BIOLOGY

Metabolomics of Mycobacterium tuberculosis Reveals Compartmentalized Co-Catabolism of Carbon Substrates

(2010) Luiz Pedro S. de Carvalho et al.   CHEMISTRY & BIOLOGY

Reduction of Clofazimine by Mycobacterial Type 2 NADH:Quinone Oxidoreductase

(2010) Takahiro Yano et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Efflux‐Pump–Derived Multiple Drug Resistance to Ethambutol Monotherapy inMycobacterium tuberculosisand the Pharmacokinetics and Pharmacodynamics of Ethambutol

(2010) Shashikant Srivastava et al.   JOURNAL OF INFECTIOUS DISEASES

Membrane transporters in drug development

(2010)   NATURE REVIEWS DRUG DISCOVERY

Targeting bacterial membrane function: an underexploited mechanism for treating persistent infections

(2010) Julian G. Hurdle et al.   NATURE REVIEWS MICROBIOLOGY

Nutrient-starved, non-replicating Mycobacterium tuberculosis requires respiration, ATP synthase and isocitrate lyase for maintenance of ATP homeostasis and viability

(2009) M. Gengenbacher et al.   MICROBIOLOGY-SGM

The protonmotive force is required for maintaining ATP homeostasis and viability of hypoxic, nonreplicating Mycobacterium tuberculosis

(2008) S. P. S. Rao et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA